CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network

Neoplasia (United States)

Volumn 15, Issue 1, 2013, Pages 85-94

  Boissonnas, Alexandre ^a,b   Licata, Fabrice ^a,b   Poupel, Lucie ^a,b   Jacquelin, Sébastien ^a,b   Fetler, Luc ^c   Krumeich, Sophie ^d   Théry, Clotilde ^d   Amigorena, Sébastian ^d   Combadière, Christophe ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CNRS   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD45 ANTIGEN; CD69 ANTIGEN; COLLAGEN FIBER; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GLYCOPROTEIN P 15095;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HISTOLOGY; KIDNEY TUMOR; LASER MICROSCOPY; MOUSE; MULTIPHOTON MICROSCOPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SARCOMA; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DENDRITIC CELL; TUMOR GROWTH; TUMOR VOLUME;

EID: 84873051750     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121572     Document Type: Article

References (37)

1. Ramakrishnan R, Antonia S, and Gabrilovich DI (2008). Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunol Immunother 57, 1523-1529.
2. Schlom J, Arlen PM, and Gulley JL (2007). Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 13, 3776-3782.
3. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26, 5233-5239.
4. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13, 1050-1059.
5. Ghiringhelli F, Apetoh L, Housseau F, Kroemer G, and Zitvogel L (2007). Links between innate and cognate tumor immunity. Curr Opin Immunol 19, 224-231.
6. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, and Hodge JW (2004). Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64, 7985-7994.
7. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, and Gabrilovich DI (2010). Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 120, 1111-1124.
8. Luznik L, Jones RJ, and Fuchs EJ (2010). High-dose cyclophosphamide for graftversus-host disease prevention. Curr Opin Hematol 17, 493-499.
9. Greenberg PD, Kern DE, and Cheever MA (1985). Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2-T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 161, 1122-1134.
10. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854.
11. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, and Chauffert B (2007). Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56, 641-648.
12. LutsiakME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, and Sabzevari H (2005). Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105, 2862-2868.
13. North RJ (1982). Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155, 1063-1074.
14. Berraondo P, Nouze C, Preville X, Ladant D, and Leclerc C (2007). Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 67, 8847-8855.
15. Zitvogel L, Apetoh L, Ghiringhelli F, and Kroemer G (2008). Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8, 59-73.
16. Pollard JW (2009). Trophic macrophages in development and disease. Nat Rev Immunol 9, 259-270.
17. Gabrilovich DI and Nagaraj S (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9, 162-174.
18. Mantovani A, Sozzani S, Locati M, Schioppa T, Saccani A, Allavena P, and Sica A (2004). Infiltration of tumours by macrophages and dendritic cells: tumourassociated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Novartis Found Symp 256, 137-145; discussion 146-138, 259-169.
19. Engelhardt JJ, Boldajipour B, Beemiller P, Pandurangi P, Sorensen C, Werb Z, Egeblad M, and Krummel MF (2012). Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21, 402-417.
20. Lindquist RL, Shakhar G, Dudziak D, Wardemann H, Eisenreich T, Dustin ML, and Nussenzweig MC (2004). Visualizing dendritic cell networks in vivo. Nat Immunol 5, 1243-1250.
21. Restifo NP, Spiess PJ, Karp SE, Mule JJ, and Rosenberg SA (1992). A nonimmunogenic sarcoma transduced with the cDNA for interferon γ elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J ExpMed 175, 1423-1431.
22. Zeelenberg IS, Ostrowski M, Krumeich S, Bobrie A, Jancic C, Boissonnas A, Delcayre A, Le Pecq JB, Combadiere B, Amigorena S, et al. (2008). Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res 68, 1228-1235.
23. Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, and Amigorena S (2007). In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 204, 345-356.
24. Boissonnas A, Scholer-Dahirel A, Simon-Blancal V, Pace L, Valet F, Kissenpfennig A, Sparwasser T, Malissen B, Fetler L, and Amigorena S (2010). Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 32, 266-278.
25. de Bruijn MF, Slieker WA, van der Loo JC, Voerman JS, van Ewijk W, and Leenen PJ (1994). Distinct mouse bone marrow macrophage precursors identified by differential expression of ER-MP12 and ER-MP20 antigens. Eur J Immunol 24, 2279-2284.
26. Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, and Leenen PJ (2004). Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 172, 4410-4417.
27. Biswas SK and Mantovani A (2010). Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11, 889-896.
28. Condeelis J and Pollard JW (2006). Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263-266.
29. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, and Mantovani A (2008). Macrophage polarization in tumour progression. Semin Cancer Biol 18, 349-355.
30. Allavena P, Sica A, Solinas G, Porta C, and Mantovani A (2008). The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66, 1-9.
31. Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al Ghuzlan A, Bidart JM, Chouaib S, Schlumberger M, and Dupuy C (2011). Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One 6, e22567.
32. Salem ML, Diaz-Montero CM, Al-Khami AA, El-Naggar SA, Naga O, Montero AJ, Khafagy A, and Cole DJ (2009). Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol 182, 2030-2040.
33. Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, Panageas KS, Merghoub T, Wolchok JD, and Houghton AN (2010). Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 115, 4384-4392.
34. Salem ML, Al-Khami AA, El-Naggar SA, Diaz-Montero CM, Chen Y, and Cole DJ (2010). Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J Immunol 184, 1737-1747.
35. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, et al. (2011). Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 71, 768-778.
36. Salem ML, El-Naggar SA, and Cole DJ (2011). Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cell Immunol 261, 134-143.
37. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, Fein M, Rasch MG, Tan YX, Qiu J, et al. (2012). Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21, 488-503.